COST-UTILITY ANALYSES OF GLOFITAMAB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY IN ITALY

Bellone M[1], Ghislieri D[2], Pradelli L[1], Kokaliaris C[3], Di Maio D[3]

[1] AdRes HEOR, Torino, TO, Italy

[2] Roche spa, Monza, Italy;

[3] F. Hoffmann-La Roche Ltd, Basel, Switzerland

Model results

Summary results for each comparator are presented in Table 1.

Table 1 – Summary results.

Vs. Tafa+len	Glofitamab (Tafa+len population)	Tafa+len	Δ
Total LYs	**6.68**	**5.84**	**0.84**
PFS	5.27	4.17	1.11
PPS	1.41	1.67	-0.27
Total QALYs	**5.61**	**4.78**	**0.83**
PFS	4.52	3.48	1.03
PPS	1.09	1.30	-0.21
Overall costs (€)	**121,958**	**508,523**	**-386,565**
Treatment	65,731	442,443	-376,712
Including drug acquisition cost	*56,783*	*431,799*	*-375,016*
Administration	358	4,279	-3,921
Adverse events	928	6,050	-5,122
Disease monitoring	54,942	55,751	-809

Tafa+len: tafasitamab plus lenalidomide

Vs. Pola-BR	Glofitamab (Pola-BR population)	Pola-BR	Δ
Total LYs	**2.96**	**2.95**	**0.00**
PFS	2.26	1.74	0.52
PPS	0.70	1.21	-0.52
Total QALYs	**2.48**	**2.44**	**0.05**
PFS	1.94	1.49	0.45
PPS	0.54	0.94	-0.40
Overall costs (€)	**106,516**	**113,394**	**-6,878**
Treatment	61,233	69,183	-7,951
Including drug acquisition cost	*56,783*	*61,460*	*-4,677*
Administration	358	288	70
Adverse events	928	1,945	-1,017
Disease monitoring	43,998	41,978	2,020

Pola-BR: Polatuzumab vedotin with rituximab and bendamustina

Vs. Kym	Glofitamab (Kym population)	Kym	Δ
Total LYs	**5.45**	**5.14**	**0.31**
PFS	4.85	3.95	0.90
PPS	0.60	1.19	-0.59
Total QALYs	**4.63**	**4.32**	**0.31**
PFS	4.16	3.39	0.77
PPS	0.47	0.93	-0.46
Overall costs (€)	**115,303**	**410,251**	**-294,949**
Treatment	60,596	298,399	-237,803
Including drug acquisition cost	*56,783*	*290,814*	*-234,031*
Administration	358	60,643	-60,285
Adverse events	928	1,494	-566
Disease monitoring	53,420	49,715	3,705

Kym: yisagenlecleucel

Vs. Yesc	Glofitamab (Yesc population)	Yesc	Δ
Total LYs	**3.96**	**7.26**	**-3.30**
PFS	3.22	6.62	-3.39
PPS	0.74	0.64	0.10
Total QALYs	**3.34**	**6.18**	**-2.84**
PFS	2.76	5.67	-2.91
PPS	0.58	0.50	0.07
Overall costs (€)	**110,238**	**426,637**	**-316,399**
Treatment	61,500	302,240	-240,740
Including drug acquisition cost	*56,783*	*298,137*	*-241,354*
Administration	358	60,643	-60,285
Adverse events	928	4,368	-3,440
Disease monitoring	47,451	59,387	-11,935

Yesc: Axicabtagene ciloleucel

Scenario analysis

Summary scenario analyses for each comparator are presented in Table 2.

Table 2 – Scenario analysis vs base case (lifetime): glofitamab vs.

vs. Polatuzumab + bendamustina + rituximab

Item	Description	Base case value	Scenario value	ICER (€/QALY)
Base case →				Dominant
Scenario analysis ↓				
Discount		3%	0%	Cost-effective (WTP<€40K/QALY) Delta QALYs= -0.05 Delta costs= -7,369
Discount		3%	5%	Dominant
log-normal distribution	Log-normal parametric distribution for PFS and OS was chosen for both treatments	Generalized Gamma both for Glofitamab and Pola-BR	Log-normal for Glofitamab and Pola-BR	Dominant

Pola-BR: Polatuzumab vedotin with rituximab and bendamustina

vs. Tafasitamab + lenalidomide

Item	Description	Base case value	Scenario value	ICER (€/QALY)
Base case →				Dominant
Scenario analysis ↓				
Discount		3%	0%	Dominant
Discount		3%	5%	Dominant
Generalized Gamma for tafa+len	The same parametric distributions for PFS and OS were chosen for both treatments	Generalized gamma for glofitamab Log-normal for tafa+len	Generalized Gamma for both treatments	Dominant
Log-normal distribution for glofitamab	Log-normal parametric distribution for PFS and OS was chosen for both treatments	Generalized gamma for glofitamab Log-normal for tafa+len	Log-normal for both treatments	Cost-effective (WTP<€40K/QALY) Delta QALYs= -0.99 Delta costs= -€393,549

Tafa+len: tafasitamab plus lenalidomide

vs. Kymriah

Item	Description	Base case value	Scenario value	ICER (€/QALY)
Base case →				Dominant
Scenario analysis ↓				
Discount		3%	0%	Dominant
Discount		3%	5%	Dominant
Log-normal distribution	Log-normal parametric distribution for PFS and OS were chosen for both treatments, based on AIC and BIC (best rank)	Generalized gamma	Log-normal	Dominant

Kym: yisagenlecleucel

vs. Yescarta

Item	Description	Base case value	Scenario value	ICER (€/QALY)
Base case →				Cost-effective (WTP<€40K/QALY)
Scenario analysis ↓				
Discount		3%	0%	Cost-effective (WTP<€40K/QALY)
Discount		3%	5%	Cost-effective (WTP<€40K/QALY)
Generalized Gamma distribution for Yesc	Generalized gamma distribution was chosen for PFS and OS for Yesc	Gompertz	Generalized gamma	Cost-effective (WTP<€40K/QALY)
Log-normal distribution	Log-normal parametric distribution for PFS and OS was chosen for both treatments	Generalized gamma for glofitamab and Gompertz for Yescarta	Log-normal	Cost-effective (WTP<€40K/QALY)

Yesc: Axicabtagene ciloleucel